Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Based on genomic analysis, 50% of high-grade serous ovarian cancers (HGSC) are predicted to have DNA repair defects. Whether this substantial subset of HGSCs actually have functional repair defects remains unknown. Here, we devise a platform for functional profiling of DNA repair in short-term patient-derived HGSC organoids. We tested 33 organoid cultures derived from 22 patients with HGSC for defects in homologous recombination (HR) and replication fork protection. Regardless of DNA repair gene mutational status, a functional defect in HR in the organoids correlated with PARP inhibitor sensitivity. A functional defect in replication fork protection correlated with carboplatin and CHK1 and ATR inhibitor sensitivity. Our results indicate that a combination of genomic analysis and functional testing of organoids allows for the identification of targetable DNA damage repair defects. Larger numbers of patient-derived organoids must be analyzed to determine whether these assays can reproducibly predict patient response in the clinic. Significance: Patient-derived ovarian tumor organoids grow rapidly and match the tumors from which they are derived, both genetically and functionally. These organoids can be used for DNA repair profiling and therapeutic sensitivity testing and provide a rapid means of assessing targetable defects in the parent tumor, offering more suitable treatment options. Cancer Discov; 8(11); 1404–21. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [125]
In the citing paper
“PDOs are a validated preclinical model to evaluate anti-cancer drug efficacy [24,25].”
From Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer (2024) · cites this paper as [24]
In the citing paper
“Patient-derived organoids or tumoroids retain cellular heterogeneity and immune cells, thus are able to more strongly recapitulate a three-dimensional (3D) tumor microenvironment ex vivo compared to homogeneous cell lines (Hill et al., 2018; Kopper et al., 2019).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“Ovarian tumoroid cultures have been established from both ascitic fluid and primary tumors, to date primarily from the more common HGSOC but also from LGSOC, MOC, OCCC, and EnOC (Hill et al., 2018; De Witte et al., 2020; Nanki et al., 2020).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“In contrast, it has been noted that organoid propagation methods tend to be selective and result in a cell population that may not be representative of the original tumor heterogeneity and in turn, treatment response, particularly in patients who have undergone previous neoadjuvant therapy (Hill et al., 2018).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880 · cited 2×
“2 and Table 1), because olaparib sensitivity is a useful surrogate marker for an HR defect (7).”
BackgroundAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citationOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790 · cited 1×
“Large-scale studies of organoids, with comparison with patient outcomes, will be required to prove the utility of this model system in the clinic (18, 19, 21).”
ResultWhole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569 · cited 2×
“NOVEMBER 2018 CANCER DISCOVERY | 1419 Human tumors derived from several tissue types exhibit clonal heterogeneity (22, 46), and functional assays in organoids can be used to address the effects of genomic tumor heterogeneity on therapeutic response.”
BackgroundOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Cited by
Cancer modeling meets human organoid technology
Tuveson, D., & Clevers, H. (2019) · Science · doi:10.1126/science.aaw6985 · Cited by 935
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Kopper, O., de Witte, C. J., Lõhmussaar, K., Valle-Inclan, J. E., Hami, N., Kester, L., Balgobind, A. V., Korving, J., Proost, N., Begthel, H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0422-6 · Cited by 834
Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
Yao, Y., Xu, X., Yang, L., Zhu, J., Wan, J., Shen, L., Xia, F., Fu, G., Deng, Y., Pan, M., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.10.010 · Cited by 755
Establishment of patient-derived cancer organoids for drug-screening applications
Driehuis, E., Kretzschmar, K., & Clevers, H. (2020) · Nature Protocols · doi:10.1038/s41596-020-0379-4 · Cited by 654
Human Organoids: Tools for Understanding Biology and Treating Diseases
Schutgens, F., & Clevers, H. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032611 · Cited by 510
Miller, R. E., Leary, A., Scott, C. L., Serra, V., Lord, C. J., Bowtell, D., Chang, D. K., Garsed, D. W., Jonkers, J., Ledermann, J. A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2102 · Cited by 483
Self-citationNext-generation cancer organoids
LeSavage, B. L., Suhar, R. A., Broguiere, N., Lutolf, M. P., & Heilshorn, S. C. (2022) · Nature Materials · doi:10.1038/s41563-021-01057-5 · Cited by 468
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Organoid Models of Tumor Immunology
Yuki, K., Cheng, N., Nakano, M., & Kuo, C. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.010 · Cited by 402
“Organoid biobanks have been established from multiple types of cancer, including colon [30,34,40,63,64], rectum, stomach [31,65], pancreas [66], liver [67,68], breast [32], ovary [69,70], and prostate [71], with distribution through entities such as the Human Cancer Models Initiative (HCMI)i.”
BackgroundTargeting replication stress in cancer therapy
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 359
Self-citationImmunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Yang, C., Xia, B.-R., Zhang, Z.-C., Zhang, Y.-J., Lou, G., & Jin, W.-L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577869 · Cited by 350
“They found that HR deficiency is related to PARP inhibitor sensitivity, and that replication fork protection deficiency is correlated with carboplatin and CHK1 and ATR inhibitor sensitivity (161).”
BackgroundSelf-citationTumor organoids: Opportunities and challenges to guide precision medicine
Veninga, V., & Voest, E. E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.020 · Cited by 339
Human disease models in drug development
Loewa, A., Feng, J. J., & Hedtrich, S. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00063-3 · Cited by 331
de Witte, C. J., Espejo Valle-Inclan, J., Hami, N., Lõhmussaar, K., Kopper, O., Vreuls, C. P. H., Jonges, G. N., van Diest, P., Nguyen, L., Clevers, H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107762 · Cited by 303
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Färkkilä, A., Gulhan, D. C., Casado, J., Jacobson, C. A., Nguyen, H., Kochupurakkal, B., Maliga, Z., Yapp, C., Chen, Y.-A., Schapiro, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15315-8 · Cited by 299
Self-citationPlatinum Resistance in Ovarian Cancer: Role of DNA Repair
Damia, G., & Broggini, M. (2019) · Cancers · doi:10.3390/cancers11010119 · Cited by 298
“Homologous recombination deficiency could also result from PTEN homozygous loss, reported in about 7% of HGSOC and EMSY amplification in 6% of tumors.”
BackgroundInfluentialXuan, Y., Wang, H., Yung, M. M., Chen, F., Chan, W.-S., Chan, Y.-S., Tsui, S. K., Ngan, H. Y., Chan, K. K., & Chan, D. W. (2022) · Theranostics · doi:10.7150/thno.70194 · Cited by 250
“For tumor digestion, according to the protocol [12], fresh tumor tissues were cut into small pieces (2 mm), digested with 2.5 mg/mL collagenase type II and DNAse, and shaken at 37 °C for 30 mins.”
MethodInfluentialStable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment
Hoffmann, K., Berger, H., Kulbe, H., Thillainadarasan, S., Mollenkopf, H., Zemojtel, T., Taube, E., Darb‐Esfahani, S., Mangler, M., Sehouli, J., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019104013 · Cited by 252
“Several studies have investigated drug responses of different patient-derived 3D models of HGSOC in short-term culture, but conditions suitable for stable long-term cultivation and creation of biobanks have remained elusive (Hill et al , 2018; Maru et al , 2019; Phan et al , 2019).”
Biomarker-Guided Development of DNA Repair Inhibitors
Cleary, J. M., Aguirre, A. J., Shapiro, G. I., & D’Andrea, A. D. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.035 · Cited by 225
Self-citationThorel, L., Perréard, M., Florent, R., Divoux, J., Coffy, S., Vincent, A., Gaggioli, C., Guasch, G., Gidrol, X., Weiswald, L.-B., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01272-5 · Cited by 236
“It has been applied to PDTO derived from ovarian tumors with potential success in identifying patients who are likely to bene fi t from treatment with PARP inhibitors 22,94 .”
MethodKonstantinopoulos, P. A., Cheng, S.-C., Wahner Hendrickson, A. E., Penson, R. T., Schumer, S. T., Doyle, L. A., Lee, E. K., Kohn, E. C., Duska, L. R., Crispens, M. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30180-7 · Cited by 225
Self-citationRational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 210
Sanij, E., Hannan, K. M., Xuan, J., Yan, S., Ahern, J. E., Trigos, A. S., Brajanovski, N., Son, J., Chan, K. T., Kondrashova, O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16393-4 · Cited by 214
Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer
Lõhmussaar, K., Oka, R., Espejo Valle-Inclan, J., Smits, M. H. H., Wardak, H., Korving, J., Begthel, H., Proost, N., van de Ven, M., Kranenburg, O. W., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.03.012 · Cited by 211
“…tissues and tumors, including normal fallopian tubes (Kessler et al., 2015; Kopper et al., 2019), ovarian surface epithelium (Kop-per et al., 2019), endometrium (Boretto et al., 2017; Turco et al., 2017), and the associated cancers (Boretto et al., 2019; Hill et al., 2018; Kopper et al., 2019).”
Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer
Chen, P., Zhang, X., Ding, R., Yang, L., Lyu, X., Zeng, J., Lei, J. H., Wang, L., Bi, J., Shao, N., et al. (2021) · Advanced Science · doi:10.1002/advs.202101176 · Cited by 200
Wang, H.-M., Zhang, C.-Y., Peng, K.-C., Chen, Z.-X., Su, J.-W., Li, Y.-F., Li, W.-F., Gao, Q.-Y., Zhang, S.-L., Chen, Y.-Q., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100911 · Cited by 192
Wan, C., Keany, M. P., Dong, H., Al-Alem, L. F., Pandya, U. M., Lazo, S., Boehnke, K., Lynch, K. N., Xu, R., Zarrella, D. T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1674 · Cited by 193
“levels when in co-culture with the HGSC cell line OVCAR8 or organoid line 17-116 (47) indicating increased immune activity (Figure 7D and S14D).”
BackgroundSelf-citationDeveloping Organoids from Ovarian Cancer as Experimental and Preclinical Models
Maenhoudt, N., Defraye, C., Boretto, M., Jan, Z., Heremans, R., Boeckx, B., Hermans, F., Arijs, I., Cox, B., Van Nieuwenhuysen, E., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.03.004 · Cited by 186
“Extensive comparison with the culture conditions of other recent OC organoid studies (Hill et al., 2018; Maru et al., 2019) was not performed.”
ResultApplications of organoids for cancer biology and precision medicine
Lo, Y.-H., Karlsson, K., & Kuo, C. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0102-y · Cited by 182
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment
Schoutrop, E., Moyano-Galceran, L., Lheureux, S., Mattsson, J., Lehti, K., Dahlstrand, H., & Magalhaes, I. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.027 · Cited by 176
Patient-derived organoids in precision cancer medicine
Tong, L., Cui, W., Zhang, B., Fonseca, P., Zhao, Q. C., Zhang, P., Xu, B., Zhang, Q., Li, Z., Seashore-Ludlow, B. A., et al. (2024) · Med · doi:10.1016/j.medj.2024.08.010 · Cited by 208
Nanki, Y., Chiyoda, T., Hirasawa, A., Ookubo, A., Itoh, M., Ueno, M., Akahane, T., Kameyama, K., Yamagami, W., Kataoka, F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69488-9 · Cited by 165
Somatic cell-derived organoids as prototypes of human epithelial tissues and diseases
Fujii, M., & Sato, T. (2021) · Nature Materials · doi:10.1038/s41563-020-0754-0 · Cited by 165
Organoid cultures for cancer modeling
Yan, H. H. N., Chan, A. S., Lai, F. P.-L., & Leung, S. Y. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.05.012 · Cited by 159
Efficient Use of Patient-Derived Organoids as a Preclinical Model for Gynecologic Tumors
Maru, Y., Tanaka, N., Itami, M., & Hippo, Y. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.05.005 · Cited by 162
Waks, A. G., Cohen, O., Kochupurakkal, B., Kim, D., Dunn, C. E., Buendia Buendia, J., Wander, S., Helvie, K., Lloyd, M. R., Marini, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.008 · Cited by 159
Self-citationA highly annotated database of genes associated with platinum resistance in cancer
Huang, D., Savage, S. R., Calinawan, A. P., Lin, C., Zhang, B., Wang, P., Starr, T. K., Birrer, M. J., & Paulovich, A. G. (2021) · Oncogene · doi:10.1038/s41388-021-02055-2 · Cited by 162
Pillay, N., Tighe, A., Nelson, L., Littler, S., Coulson‐Gilmer, C., Bah, N. K., Golder, A., Bakker, B., Spierings, D. C. J., James, D. I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.004 · Cited by 161
“Also, DNA fiber assays in short-term ovarian cancer cultures found that 61%displayed unstable replication forks (Hill et al., 2018).”
BackgroundParmar, K., Kochupurakkal, B. S., Lazaro, J., Wang, Z. C., Palakurthi, S. S., Kirschmeier, P. T., Yang, C., Sambel, L. A., Färkkilä, A., Reznichenko, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0448 · Cited by 152
“We have previously observed this phenomenon when prexasertib combined with a replication stress-inducing agent such as gemcitabine produced greater fork instability than prexasertib alone in HGSOC organoids with stabilized replication forks (40).”
BackgroundSelf-citationOrganoid based personalized medicine: from bench to bedside
Li, Y., Tang, P., Cai, S., Peng, J., & Hua, G. (2020) · Cell Regeneration · doi:10.1186/s13619-020-00059-z · Cited by 136
Leveraging the replication stress response to optimize cancer therapy
Cybulla, E., & Vindigni, A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00518-6 · Cited by 153
Exploiting DNA repair defects in colorectal cancer
Reilly, N. M., Novara, L., Nicolantonio, F. D., & Bardelli, A. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12467 · Cited by 141
“Defects in replication fork protection are correlated with sensitivity to ATR inhibitors (ATRi), and patients who do not exhibit defects in HR but have unstable replication forks may benefit from ATRi therapies (Hill et al., 2018).”
BackgroundSimoneau, A., Xiong, R., & Zou, L. (2021) · Genes & Development · doi:10.1101/gad.348479.121 · Cited by 131
“Recent studies showed that a DNA fiber assay can be applied to patient-derived orga-noids or circulating tumor cells to monitor the replication stress response, which may be used to predict the response of patients to PARPi (Yazinski et al. 2017; Hill et al. 2018).”
Organoid systems to study the human female reproductive tract and pregnancy
Alzamil, L., Νικολακοπούλου, Κ., & Turco, M. Y. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0565-5 · Cited by 130
“3D cultures from solid tumors, ascitic, and pleural fluid of patients with ovarian carcinoma were generated [103].”
BackgroundCancer research using organoid technology
Kretzschmar, K. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01990-z · Cited by 120
“Establishment of cancer organoid cultures has been described for primary and/or metastatic tumour tissue sampled from the bladder [14, 69], brain [70, 71], breast [15], colon [17, 72–74], endometrium [18, 75], head and neck [25, 68], kidney [76, 77], liver [78], lung [23], oesophagus [17], ovaries [79, 80], pancreas […”
BackgroundSenkowski, W., Gall-Mas, L., Falco, M. M., Li, Y., Lavikka, K., Kriegbaum, M. C., Oikkonen, J., Bulanova, D. R., Pietras, E. J., Voßgröne, K., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.04.012 · Cited by 135
3D and organoid culture in research: physiology, hereditary genetic diseases and cancer
Suarez-Martinez, E., Suazo-Sanchez, I., Celis-Romero, M., & Carnero, A. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00775-w · Cited by 118
Millen, R., de Kort, W. W. B., Koomen, M., van Son, G. J. F., Gobits, R., de Vries, B. B. L. P., Begthel, H., Zandvliet, M. M. J. M., Doornaert, P., Raaijmakers, C. P. J., et al. (2023) · Med · doi:10.1016/j.medj.2023.04.003 · Cited by 143
Targeting ATR in patients with cancer
Ngoi, N. Y. L., Pilie, P. G., McGrail, D. J., Zimmermann, M., Schlacher, K., & Yap, T. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00863-5 · Cited by 128
“In patient-derived ovarian cancer organoids, the presence of replication fork instability determined using DNA fibre assays was associated with a response to ATR inhibitors and gemcitabine 162 (Fig.”
Ragupathi, A., Singh, M., Perez, A. M., & Zhang, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1133472 · Cited by 133
“For example, in a recent publication, Hill and colleagues established a panel of patientderived ovarian cancer organoids and attempted to predict how well they respond to various DNA repair inhibitors, including the olaparib, using a variety of molecular, cellular and genomic biomarkers (Hill et al., 2018).”
BackgroundCancer organoid co-culture model system: Novel approach to guide precision medicine
Yuan, J., Li, X., & Yu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061388 · Cited by 125
Minoli, M., Cantore, T., Hanhart, D., Kiener, M., Fedrizzi, T., Manna, F. L., Karkampouna, S., Chouvardas, P., Genitsch, V., Rodríguez-Calero, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37696-2 · Cited by 127
“However, the concordance between PDO and PT genomic pro fi les represents a key feature of PDOs, not only in bladder 12,26 and upper urinary tract urothelial cancers (UTUC) 27 but also in other cancer types 14,17 – 19 , 28 .”
BackgroundA pan-cancer organoid platform for precision medicine
Larsen, B. M., Kannan, M., Langer, L. F., Leibowitz, B. D., Bentaieb, A., Cancino, A., Dolgalev, I., Drummond, B. E., Dry, J. R., Ho, C.-S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109429 · Cited by 105
Gralewska, P., Gajek, A., Marczak, A., & Rogalska, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00874-6 · Cited by 116
Dadgar, N., Gonzalez-Suarez, A. M., Fattahi, P., Hou, X., Weroha, J. S., Gaspar-Maia, A., Stybayeva, G., & Revzin, A. (2020) · Microsystems & Nanoengineering · doi:10.1038/s41378-020-00201-6 · Cited by 99
Organoids of the female reproductive tract
Chumduri, C., & Turco, M. Y. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02028-0 · Cited by 123
Zhang, X., Yao, J., Li, X., Niu, N., Liu, Y., Hajek, R. A., Peng, G., Westin, S. N., Sood, A. K., & Liu, J. (2023) · Science Advances · doi:10.1126/sciadv.adf7195 · Cited by 110
Self-citationScattolin, T., Bortolamiol, E., Visentin, F., Palazzolo, S., Caligiuri, I., Perin, T., Canzonieri, V., Demitri, N., Rizzolio, F., & Togni, A. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202002199 · Cited by 105
3D cancer models: One step closer to in vitro human studies
Manduca, N., Maccafeo, E., Maria, R. D., Sistigu, A., & Musella, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175503 · Cited by 109
A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity
Nelson, L., Tighe, A., Golder, A., Littler, S., Bakker, B., Moralli, D., Baker, S. M., Donaldson, I. J., Spierings, D. C. J., Wardenaar, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14551-2 · Cited by 100
Microfluidic Organoids-on-a-Chip: Quantum Leap in Cancer Research
Duzagac, F., Saorin, G., Memeo, L., Canzonieri, V., & Rizzolio, F. (2021) · Cancers · doi:10.3390/cancers13040737 · Cited by 96
“In 2009, Sato T. et al. demonstrated that Lgr5+ stem cells isolated from the intestinal crypt or crypt itself have the ability to form intestinal crypt-villus units, which are self-regulating organoid structures without a non-epithelial cellular niche by using Matrigel supplemented with growth factors.”
BackgroundInfluentialBRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality
Li, X., & Zou, L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci181062 · Cited by 118
“Consistent with this hypothesis, in organoids derived from PARPi-resistant, HR-defective ovarian cancer patients, fork protection is restored (88).”
BackgroundPaffenholz, S. V., Salvagno, C., Ho, Y.-J., Limjoco, M., Baslan, T., Tian, S., Kulick, A. R., de Stanchina, E., Wilkinson, J. E., Barriga, F. M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117754119 · Cited by 96
“The DNA-damage response was determined using IF for 53BP1, γH2AX, and Rad51 (18).”
BackgroundMethodExploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy
Patterson-Fortin, J., & D’Andrea, A. D. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1672 · Cited by 105
Self-citationCurrent Status of Patient-Derived Ovarian Cancer Models
Maru, Y., & Hippo, Y. (2019) · Cells · doi:10.3390/cells8050505 · Cited by 95
Zhang, S., Iyer, S., Ran, H., Dolgalev, I., Gu, S. S., Wei, W., Foster, C., Loomis, C. A., Olvera, N., Dao, F., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0455 · Cited by 102
A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS
Duan, X., Zhang, T., Feng, L., de Silva, N., Greenspun, B. C., Wang, X., Moyer, J. E., Martin, M. L., Chandwani, R., Elemento, O., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.11.011 · Cited by 89
Regulation and pharmacological targeting of RAD51 in cancer
Grundy, M. K., Buckanovich, R. J., & Bernstein, K. A. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa024 · Cited by 90
“In many cases, the organoid’s response to a particular drug therapy was analogous to the response seen in the patient after treatment with the same therapeutic (96).”
Druggable genome and precision medicine in cancer: current challenges
Dupont, C., Riegel, K., Pompaiah, M., Juhl, H. H., & Rajalingam, K. (2021) · FEBS Journal · doi:10.1111/febs.15788 · Cited by 86
Converging bioprinting and organoids to better recapitulate the tumor microenvironment
Wang, X., Luo, Y., Ma, Y., Wang, P., & Yao, R. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.11.006 · Cited by 85
Ruiz-Garcia, H. J., Alvarado-Estrada, K., Schiapparelli, P. V., Quiñones‐Hinojosa, A., & Trifiletti, D. M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.558381 · Cited by 79
“, 2015; Tuveson and Clevers, 2019); (3) organoids represent a model to study the initiation, evolution, and drug response of the original brain tumor, allowing the identification of potentially targetable therapy (Hill et al., 2018; Lee et al., 2018; Tiriac et al., 2018).”
BackgroundDrug screening model meets cancer organoid technology
Liu, C., Qin, T., Huang, Y., Li, Y., Chen, G., & Sun, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100840 · Cited by 71
Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh, K. C., Mullen, M. M., Blachut, B., Stover, E. H., Konstantinopoulos, P. A., Liu, J. F., Matulonis, U. A., Khabele, D., Mosammaparast, N., & Vindigni, A. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.08.035 · Cited by 75
Self-citationWang, E., Xiang, K., Zhang, Y., & Wang, X.-F. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.001 · Cited by 56
RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Compadre, A. J., van Biljon, L. N., Valentine, M. C., Llop‐Guevara, A., Graham, E., Fashemi, B., Herencia-Ropero, A., Kotnik, E. N., Cooper, I., Harrington, S. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3335 · Cited by 75
“Thus, they are more clinically relevant than cell lines for evaluating drug sensitivity, functionalbiomarkers, andprocesses such asDNAdamage response (29).”
Konstantinopoulos, P. A., da Costa, A. A. B. A., Gulhan, D., Lee, E. K., Cheng, S., Hendrickson, A. E. W., Kochupurakkal, B. S., Kolin, D. L., Kohn, E. C., Liu, J. F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25904-w · Cited by 72
Self-citationPatient‐derived cancer organoids for drug screening: Basic technology and clinical application
Ren, X., Chen, W., Yang, Q., Li, X., & Xu, L. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15930 · Cited by 78
Patient-Derived Organoids as a Model for Cancer Drug Discovery
Rae, C. J., Amato, F., & Braconi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073483 · Cited by 76
Bi, J., Newtson, A. M., Zhang, Y., Devor, E. J., Samuelson, M. I., Thiel, K. W., & Leslie, K. K. (2021) · Cancers · doi:10.3390/cancers13122901 · Cited by 72
“Neoadjuvant therapy has been shown to negatively affect the success rate of PDO generation [39].”
BackgroundAhmed, N., Kadife, E., Raza, A., Short, M. K., Jubinsky, P. T., & Kannourakis, G. (2020) · Cells · doi:10.3390/cells9030719 · Cited by 72
Konstantinopoulos, P. A., Lee, J., Gao, B., Miller, R. E., Lee, J., Colombo, N., Vergote, I. B., Credille, K. M., Young, S. R. L., McNeely, S., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.09.019 · Cited by 70
Self-citationYee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66
Organoid technology in female reproductive biomedicine
Khoei, H. H., Esfandiari, F., Hajari, M. A., Ghorbaninejad, Z., Piryaei, A., & Baharvand, H. (2020) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-020-00621-z · Cited by 71
Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma
Chen, H., Gotimer, K. F., Souza, C. D., Tepper, C. G., Karnezis, A. N., Leiserowitz, G. S., CHIEN, J. R., & Smith, L. H. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.03.026 · Cited by 67
Patterson-Fortin, J., Bose, A., Tsai, W.-C., Grochala, C., Nguyen, H. Q., Zhou, J., Parmar, K., Lazaro, J., Liu, J. F., McQueen, K., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1124 · Cited by 77
Self-citationHogenson, T. L., Xie, H., Phillips, W. J., Toruner, M. D., Li, J., Horn, I. P., Kennedy, D. J., Almada, L. L., Marks, D. L., Carr, R. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158060 · Cited by 75
Bhola, P. D., Ahmed, E., Guerriero, J. L., Sicińska, E., Su, E., Lavrova, E., Ni, J., Chipashvili, O., Hagan, T., Pioso, M. S., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aay1451 · Cited by 69
Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response
Spiller, E. R., Ung, N. M., Kim, S., Patsch, K., Lau, R., Strelez, C., Doshi, C., Choung, S., Choi, B., Juarez, E. F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771173 · Cited by 64
“…faithfully representing the original physiological environment, these tumor organoid models address some of the limitations of traditional cell line cultures and offer rapid, scalable approaches for patient-speci fi c molecular and phenotypic characterization as well as drug screening (11, 15 – 17).”
BackgroundCisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1
Pan, C., Kang, J., Hwang, J. S., Li, J., Boese, A. C., Wang, X., Yang, L., Boggon, T. J., Chen, G. Z., Saba, N. F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24845-8 · Cited by 67
Wu, Y., Xu, S., Cheng, S., Yang, J., & Wang, Y. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01094-5 · Cited by 78
Cancer organoids: A platform in basic and translational research
Ma, X., Wang, Q. L., Li, G., Li, H., Xu, S., & Pang, D. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.052 · Cited by 67
Tumor organoids: From inception to future in cancer research
Yang, L., Yang, S., Li, X., Li, B., Li, Y., Zhang, X., Ma, Y., Peng, X., Jin, H., Fan, Q., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.005 · Cited by 64
Self-citationNero, C., Vizzielli, G., Lorusso, D., Cesari, E., Daniele, G., Loverro, M., Scambia, G., & Sette, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01917-7 · Cited by 70
Mangogna, A., Munari, G., Pepe, F., Maffii, E., Giampaolino, P., Ricci, G., Fassan, M., Malapelle, U., & Biffi, S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020284 · Cited by 62
“In ovarian and breast cancer experimental models, including ex vivo cultures derived from ascites or solid HGSOC, decreased DNA damage-induced nuclear RAD51 foci have been associated with BRCA1 or BRCA2 gene deficiencies and PARPi responses [68].”
BackgroundCracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
Paulet, L., Trécourt, A., Leary, A. F., Péron, J., Descôtes, F., Devouassoux‐Shisheboran, M., Leroy, K., You, B., & Lopez, J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.037 · Cited by 63
Colomer, R., Miranda, J., Romero-Laorden, N., Hornedo, J., González‐Cortijo, L., Mouron, S. A., Bueno, M. J., Mondéjar, R., & Quintela-Fandiño, M. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102029 · Cited by 69
Organoid of ovarian cancer: genomic analysis and drug screening
Liu, H., Xia, B., Jin, M., & Lou, G. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02276-8 · Cited by 61
Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy
Taurin, S., Alzahrani, R., Aloraibi, S., Ashi, L., AlHarmi, R. A. R., & Hassani, N. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102226 · Cited by 59
Mullen, M. M., Lomonosova, E., Toboni, M. D., Oplt, A., Cybulla, E., Blachut, B., Zhao, P., Noia, H. M., Wilke, D., Rankin, E. B., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0302 · Cited by 62
PARP Inhibitors in Pancreatic Cancer
Brown, T. J., & Reiss, K. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000554 · Cited by 59
Metadata
- Authors
- Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., Yang, C., Morizane, R., Kochupurakkal, B. S., Do, K. T., Konstantinopoulos, P. A., Liu, J. F., Bonventre, J. V., Matulonis, U. A., Shapiro, G. I., Berkowitz, R. S., Crum, C. P., & D'Andrea, A. D.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- 1Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- ORCID
- Hill, Sarah J.
- Decker, Brennan
- Roberts, Emma A.
- Horowitz, Neil S.
- Worley, Michael J.
- Feltmate, Colleen M.
- Nucci, Marisa R.
- Swisher, Elizabeth M.
- Nguyen, Huy
- Yang, Chunyu
- Morizane, Ryuji
- Kochupurakkal, Bose S.
- Do, Khanh T.
- Konstantinopoulos, Panagiotis A.
- Liu, Joyce F.
- Bonventre, Joseph V.
- Matulonis, Ursula A.
- Shapiro, Geoffrey I.
- Berkowitz, Ross S.
- Crum, Christopher P.
- Venue
- Cancer Discovery
- Published
- 2018-11-01
- Volume
- 8
- Issue
- 11
- Pages
- 1404-1421
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6365285
- OpenAlex
- W2891058330
- Cited by
- 452
- References
- 49
- Citations by year
- 2026: 37 · 2025: 43 · 2024: 67 · 2023: 78 · 2022: 66 · 2021: 72 · 2020: 63 · 2019: 25 · 2018: 1
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Stand Up to Cancer (SU2C) (SU2C-AACR-DT16-15)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) (R37HL052725, P01HL048546)
- U.S. Department of Defense (DOD) (BC151331P1)
- Leukemia and Lymphoma Society (LLS) (6237-13)
- Breast Cancer Research Foundation (BCRF)
- Richard and Susan Smith Family Foundation
- The Bridge Project
- HHS | NIH | National Cancer Institute (NCI) (UM1 CA186709)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- high-grade serous ovarian cancer, DNA repair deficiency, patient-derived tumor organoids, homologous recombination deficiency, replication fork protection, PARP inhibitor sensitivity, carboplatin sensitivity, CHK1 inhibitor, ATR inhibitors, predictive biomarkers, targeted therapy
- MeSH terms
- Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, DNA Repair, DNA Replication, Female, Follow-Up Studies, Humans, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Organ Culture Techniques, Organoids, Ovarian Neoplasms, Prognosis, Pyrazines, Pyrazoles, Biomarkers, Tumor, Carboplatin, Cystadenocarcinoma, Serous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.